Home -> Law Blog Directory -> Patent Law Blogs -> Patently Obvious
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patently ObviousImpact of Merger/Buyout on Prior Agreement to Not Challenge Patent Validity
By Dennis Crouch, Esq.
Epistar v. ITC (and Philips Lumileds Lighting) (Fed. Cir. 2009) 07-1457.pdf
Merger: Lumileds owns a patent covering a light-emitting diode (LED) with an electrically conductive window layer that is both brighter and more efficient than other LEDs. The conductive layer helps spread the flow of electrical current avoid "current crowding."
At issue in this case is the impact of a corporate merger/buyout on a settlement agreement that included a promise to not challenge a patent's validity.
Lumileds and Epistar have signed at least two prior settlement agreements involving the patent at issue here. In those agreements, Epistar agreed to pay a licensing fee for certain products, but reserved its right to challenge the patent if Lumileds asserted the patent against other patents. A third company, UEC, agreed that neither it nor its successors would later challenge the validity of the Lumileds patents.
Subsequently, Epistar purchased UEC, and the patentee argued that UEC's agreement should also bind Epistar. On appeal, the Federal Circuit partially rejected that argument - holding that the UEC settlement continues to bind the parties, but only "as understood and intended by them, according to its ordinary terms." Thus, even though Epistar took on all the legal obligations of UEC, Epistar can still challenge the Lumileds patent if the case does not involve UEC related products.
UEC?s settlement agreement has preclusive effect upon Epistar only ?to the same extent as upon [UEC it]self.? Restatement (Second) of Judgments § 43 (1982). The preclusive effect of that agreement, if any, is limited to UEC?s pre?Epistar product lines. To paraphrase this court in International Nutrition v. Horphag Research, Epistar?s acquisition of UEC does not have the effect of limiting Epistar?s rights that are unrelated to the product lines it acquired from UEC. Accordingly, this court overturns the Commission?s final determination that Epistar is estopped from challenging validity of the ?718 patent when asserted against its own products, separate from the UEC?Lumileds settlement agreement.
Here, the court could have done well to cite the Supreme Court's decision of Lear v. Adkins and its statements favoring the ability to challenge patent validity based on on "the strong federal policy favoring the full and free use of ideas in the public domain.?
Full post as published by Patently Obvious on May 26, 2009 (boomark / email).
Prenuptial Agreements
Make an Airtight Prenuptial Agreement
Uniform Pre-marital Agreement Act
Standard Prenuptial Law
Merger Agreement Rejected
Finish Line and Genesco reach $175 million settlement in merger dispute.
Mirrors
Recalled Due to Impact and Laceration Hazards
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Ownership Transfer
Amsol to pay $5.625 million settlement in buyout lawsuit.

Assessing patent validity: Prior art can anticipate patent claim even if claim is non-obvious
Webinar on recent patent cases
Sign of the Times: Insolvency Clauses Come the Fore in Stock PUrchase Agreements
Epistar gets to challenge validity of Philips' US 5,008,718
Federal Circuit rejects challenge to the validity of the patent for the drug Plavix
No Deal: Fidelity Calls off LandAmerica Merger








